Dr Pourhassan says patients receiving 525 mg achieved a 'strong result' with a 94% response rate.
Full interview: CytoDyn sees 'strong result' in leronlimab dose escalation monotherapy trial to treat HIV
Quick facts: CytoDyn
Market Cap: $162.01 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE